Cowen and Company reiterated their hold rating on shares of Agilent Technologies, Inc. (NYSE:A) in a research note published on Thursday. The brokerage currently has a $65.00 target price on the medical research company’s stock.

Other equities research analysts have also recently issued reports about the stock. Deutsche Bank AG reiterated a buy rating and issued a $66.00 price target on shares of Agilent Technologies in a research report on Thursday, June 22nd. BidaskClub cut Agilent Technologies from a strong-buy rating to a buy rating in a research note on Tuesday, June 13th. Jefferies Group LLC reissued a buy rating and issued a $66.00 price target on shares of Agilent Technologies in a research note on Wednesday, August 9th. Barclays PLC reissued a buy rating and issued a $67.00 price target on shares of Agilent Technologies in a research note on Wednesday, July 19th. Finally, Janney Montgomery Scott lifted their price target on Agilent Technologies from $65.00 to $70.00 and gave the stock a buy rating in a research note on Wednesday, August 16th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Agilent Technologies has a consensus rating of Buy and an average price target of $64.38.

Shares of Agilent Technologies (A) opened at 64.20 on Thursday. The firm’s 50 day moving average is $62.75 and its 200 day moving average is $58.31. Agilent Technologies has a 1-year low of $42.92 and a 1-year high of $66.45. The firm has a market capitalization of $20.66 billion, a PE ratio of 33.11 and a beta of 1.30.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Tuesday, August 15th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.52 by $0.07. Agilent Technologies had a net margin of 14.36% and a return on equity of 16.95%. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the previous year, the business earned $0.49 earnings per share. Agilent Technologies’s revenue for the quarter was up 6.7% compared to the same quarter last year. Analysts anticipate that Agilent Technologies will post $2.32 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Agilent Technologies’ (A) “Hold” Rating Reiterated at Cowen and Company” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/01/agilent-technologies-a-hold-rating-reiterated-at-cowen-and-company.html.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 25th. Stockholders of record on Tuesday, October 3rd will be issued a dividend of $0.132 per share. The ex-dividend date is Monday, October 2nd. This represents a $0.53 annualized dividend and a dividend yield of 0.82%. Agilent Technologies’s dividend payout ratio is 27.32%.

In other news, Director Boon Hwee Koh sold 4,500 shares of Agilent Technologies stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $63.63, for a total transaction of $286,335.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Didier Hirsch sold 72,545 shares of Agilent Technologies stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $62.38, for a total value of $4,525,357.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 170,720 shares of company stock valued at $10,795,039.

Several institutional investors have recently made changes to their positions in A. UBS Asset Management Americas Inc. lifted its holdings in shares of Agilent Technologies by 9.8% during the 1st quarter. UBS Asset Management Americas Inc. now owns 882,075 shares of the medical research company’s stock valued at $46,635,000 after buying an additional 78,851 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in Agilent Technologies by 3.3% in the 1st quarter. Pacer Advisors Inc. now owns 6,430 shares of the medical research company’s stock worth $340,000 after purchasing an additional 205 shares during the last quarter. Clinton Group Inc. acquired a new stake in Agilent Technologies in the 1st quarter worth approximately $253,000. Cipher Capital LP lifted its holdings in Agilent Technologies by 1.4% in the 1st quarter. Cipher Capital LP now owns 75,820 shares of the medical research company’s stock worth $4,009,000 after purchasing an additional 1,026 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in Agilent Technologies by 4.9% in the 1st quarter. Victory Capital Management Inc. now owns 3,405,126 shares of the medical research company’s stock worth $180,029,000 after purchasing an additional 158,014 shares during the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Stock Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related stocks with our FREE daily email newsletter.